ANDA 205220, held by Actavis Labs Fl Inc. Valganciclovir Hydrochloride.
As of Nov 16, 2026, ANDA 205220 (Valganciclovir Hydrochloride), held by Actavis Labs Fl Inc, was first approved by FDA on Jul 18, 2016, with 3 approved supplements and 0 published complete response letters.
Valganciclovir for oral solution is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Pediatric Patients Prevention of CMV disease in kidney and heart transplant patients at high risk. 1.2 Pediatric Patients Prevention of CMV Disease: Valganciclovir is indicated for the prevention of CMV disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 18, 2016 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Valganciclovir Hydrochloride50MG/ML · for solution;oral | Valganciclovir Hydrochloride | Rx |
| Oct 19, 2026 | Supplement 17Manufacturing | Approved | None posted |
| Mar 12, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 12, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jul 18, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters